Docetaxel albumin bound

Alphamab Oncology (HKEX: 9966) revealed that anbenitamab (KN026), a bispecific anti-HER2 antibody, met its primary endpoint in the Phase III Neo-Healer trial evaluating neoadjuvant treatment of early or locally advanced HER2-positive breast cancer, with the company describing the total pathological complete response (tpCR) result as both statistically and clinically significant versus the current standard of care. Neo-Healer (KN026-004) is a randomized, open-label, multicenter Phase III study planned to enroll approximately 520 patients with early or locally advanced HER2+ breast cancer, assigned 1:1 to receive KN026 plus albumin-bound docetaxel (HB1801) ± carboplatin or trastuzumab plus pertuzumab plus docetaxel ± carboplatin, with total pathological complete response assessed by a blinded independent review committee as the primary endpoint. No numerical tpCR rates, confidence intervals, or p-values were disclosed. The announcement stated only that KN026 in combination with HB1801 ± carboplatin “significantly improved” tpCR compared with the standard regimen, with full data to be presented at an international conference. The absence of quantitative results limits any assessment of effect size at this stage. Safety data were not reported. Alphamab’s HER2 bispecific engineering Anbenitamab is engineered using Alphamab’s CRIB (Charge Repulsion Induced Bispecific) platform and binds two non-overlapping epitopes on HER2 simultaneously, blocking downstream signaling while enhancing antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and receptor downregulation. The design effectively consolidates the biological roles of trastuzumab and pertuzumab — which target distinct HER2 epitopes — into a single molecule. The experimental arm also replaces standard docetaxel with HB1801, CSPC Group’s albumin-bound docetaxel formulation, which encapsulates the active drug in human serum albumin, eliminating the polysorbate 80 and ethanol solvents associated with hypersensitivity reactions and premedication requirements. Competitive context The neoadjuvant HER2+ breast cancer setting is one where the limitations of current therapy are quantifiable. Trastuzumab plus pertuzumab combined with chemotherapy — the THP/TCbHP regimen — achieves tpCR in roughly half of patients with early or locally advanced disease. Patients who do not achieve tpCR face a materially worse prognosis and are typically escalated to adjuvant ado-trastuzumab emtansine (T-DM1). A bispecific antibody that raises the tpCR ceiling would, in principle, reduce downstream escalation requirements, though the Neo-Healer data needed to substantiate that argument have not yet been released. The competitive framing matters here. The trial’s active comparator is trastuzumab plus pertuzumab plus docetaxel — which is itself the globally established standard and the benchmark against which Roche’s Phesgo, the fixed-dose subcutaneous co-formulation of both antibodies, has positioned its convenience advantage. KN026 is not competing on route of administration but on mechanistic consolidation and, if the data support it, on efficacy magnitude. The absolute tpCR improvement will need to be evaluated carefully when full results are published. KN026’s regulatory trajectory is more advanced in gastric cancer than in breast cancer. The China National Medical Products Administration accepted a new drug application for KN026 in combination with chemotherapy for second-line or above HER2+ gastric or gastroesophageal junction cancer in September 2025, and that application remains under review. The US FDA has granted KN026 orphan drug designation for HER2+ or HER2-low gastric cancer. The NMPA also granted breakthrough therapy designation for the same gastric cancer indication. None of these designations extend to breast cancer, where KN026 remains investigational. The breast cancer program is structured as a multi-indication effort. Alongside Neo-Healer, Alphamab and its partner JMT-Bio — a subsidiary of CSPC Pharmaceutical Group (HKEX: 1093), which holds exclusive mainland China development and commercialization rights for KN026 in breast and gastric cancer — are running registrational trials in first-line HER2+ breast cancer and in the adjuvant HER2+ breast cancer setting. A Phase III adjuvant study (NCT07441460) is listed on AllSci as not yet recruiting. The partnership structure is relevant to the commercial picture. JMT-Bio’s rights cover mainland China; Alphamab retains rights elsewhere. The primary near-term market for Neo-Healer data, if regulatory submissions follow, would be China, where HER2+ breast cancer accounts for approximately 20%-30% of breast cancer cases and where roughly 75% of patients present at early or locally advanced stage — the exact population Neo-Healer enrolled. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website